Evidence map›Paper›PMID 38169190›Full record

ArticleBiomaterials2024

Atherosclerotic three-layer nanomatrix vascular sheets for high-throughput therapeutic evaluation.

Jun Chen, Xixi Zhang, Robbie Cross, Yujin Ahn, Gillian Huskin, Will Evans, Patrick Taejoon Hwang, Jeong-A Kim, Brigitta C Brott, Hanjoong Jo and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jun ChenDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA; Endomimetics, LLC., Birmingham, AL, USA.
Xixi ZhangDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA.
Robbie CrossDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA.
Yujin AhnDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA.
Gillian HuskinDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA.
Will EvansAugusta University/University of Georgia Medical Partnership, Athens, GA, USA.
Patrick Taejoon HwangEndomimetics, LLC., Birmingham, AL, USA.
Jeong-A KimDepartment of Medicine, Division of Endocrinology and Metabolism, UAB Comprehensive Diabetes Center, Birmingham, AL, USA.
Brigitta C BrottEndomimetics, LLC., Birmingham, AL, USA; Department of Medicine and Division of Cardiovascular Disease, The University of Alabama at Birmingham, AL, USA.
Hanjoong JoWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Young-Sup YoonDivision of Cardiology, School of Medicine, Emory University, Atlanta, GA, USA.
Ho-Wook JunDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA; Endomimetics, LLC., Birmingham, AL, USA. Electronic address: hwjun@uab.edu.
University of Alabama at Birmingham · USEndomimetics (United States) · USEmory University · USGeorgia Institute of Technology · USUniversity of Georgia · US

Funding

Dual action nanomatrix coated stent evaluation using engineered artery sheets with atherosclerotic featuresR01HL163802 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JUN, HO-WOOK · 2022 to 2025
$2.6M
NHLBI NIH HHS R01 HL163802
6 · The paper itself

Abstract

In vitro atherosclerosis models are essential to evaluate therapeutics before in vivo and clinical studies, but significant limitations remain, such as the lack of three-layer vascular architecture and limited atherosclerotic features. Moreover, no scalable 3D atherosclerosis model is available for making high-throughput assays for therapeutic evaluation. Herein, we report an in vitro 3D three-layer nanomatrix vascular sheet with critical atherosclerosis multi-features (VSA), including endothelial dysfunction, monocyte recruitment, macrophages, extracellular matrix remodeling, smooth muscle cell phenotype transition, inflammatory cytokine secretion, foam cells, and calcification initiation. Notably, we present the creation of high-throughput functional assays with VSAs and the use of these assays for evaluating therapeutics for atherosclerosis treatment. The therapeutics include conventional drugs (statin and sirolimus), candidates for treating atherosclerosis (curcumin and colchicine), and potential gene therapy (miR-146a-loaded liposomes). The high efficiency and flexibility of the scalable VSA functional assays should facilitate drug discovery and development for atherosclerosis.

Indexed as

AtherosclerosisPlaque, AtheroscleroticFoam CellsGene ExpressionHumansMacrophagesMonocytesMyocytes, Smooth Muscle3D in vitro modelsAtherosclerosisDrug evaluationHigh-throughputVascular sheet

Identifiers

PMID38169190
PMCPMC10843643
OpenAlexW4390278712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.